Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis

Eur Respir J. 2020 Aug 27;56(2):2000175. doi: 10.1183/13993003.00175-2020. Print 2020 Aug.

Authors

Mordechai Pollak¹, Michelle Shaw², David Wilson³, Hartmut Grasemann^{3

2}, Felix Ratjen^{3

2}

Affiliations

¹ Division of Respiratory Medicine, Hospital for Sick Children, Toronto, ON, Canada [email protected].
² Translational Medicine, Sickkids Research Institute, Toronto, ON, Canada.
³ Division of Respiratory Medicine, Hospital for Sick Children, Toronto, ON, Canada.

PMID: 32269091
DOI: 10.1183/13993003.00175-2020

No abstract available

Publication types

Letter

MeSH terms

Antifungal Agents / therapeutic use
Aspergillosis, Allergic Bronchopulmonary* / drug therapy
Aspergillus fumigatus
Bronchodilator Agents / therapeutic use
Child
Cystic Fibrosis* / complications
Cystic Fibrosis* / drug therapy
Humans

Substances

Antifungal Agents
Bronchodilator Agents